AI assistant
CADOUX LIMITED — Board/Management Information 2007
Jul 23, 2007
64620_rns_2007-07-23_082ab077-4e2c-40ba-9cda-64281c5ba57a.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [157 x 102] intentionally omitted <==
APPOINTMENT OF DIRECTOR
Summary
• Mr. Russell Barnett appointed to the Board of Directors
Perth, Australia. 24 July 2007 : The Company (ASX: SBP) is pleased to announce that it has appointed Mr. Russell Barnett as a Director of the Company.
Mr. Barnett has over 15 years experience in technology commercialization, innovation management, new venture creation and venture capital markets with a wide range of organizations throughout the Asia Pacific region. He is the Principal and founder of Australian Venture Consultants Pty Ltd, a management consulting practice providing expertise in these areas to universities, research funding agencies and other innovation intensive organizations. Mr. Barnett holds a number of other directorships including Chairman of Kirke Securities Limited and non-executive director of Rewire Therapies Limited.
Mr. Barnett’s experience and range of contacts will be of considerable benefit to the Company particularly in areas of strategy and innovation.
- End -
Further Information:
David Sparling Tony Kiernan General Manager Chairman Tel: (08) 9446 7555 Tel: (08) 9446 7555 Mob: 0417 721 972 Mob: 0418 912 843 Email: [email protected] Email: [email protected]
About Solbec
Solbec Pharmaceuticals Ltd identifies naturally-occurring compounds with potential in the development of better therapies for debilitating conditions and life-threatening diseases. With the assistance of a $2.26M Australian Government Commercial Ready grant the company is currently progressing its key project, Coramsine[®] for the treatment of advanced solid tumours. The two proprietary ingredients of Coramsine[®] were isolated from the fruit of the Devil’s Apple ( Solanum linnaeanum ). They show activity against some cancers and cause potentially therapeutic changes to the immune system. In addition to human health, Coramsine[®] has potential application to animal health and diagnostics. Solbec’s business strategy is to partner or out-license Coramsine[®] for the final stages of pre-commercial development and marketing.
Page 1 of 1 Solbec/ASX Release 15-5-06